method for prophylaxis or treatment of a dengue virus infection, method for inducing a cytotoxic t-lymphocyte mediated immune response, dengue virus vaccine, method for preventing a dengue virus disease, and method for inducing an immune response to at least one dengue virus

摘要

Abstract cytotoxic T-lymphocyte-inducing immunogenes for the prevention, treatment and diagnosis of dengue fever (DHF) and dengue hemorrhagic fever (DHR) infection are globally significant public health issues and understanding the overall immune response to infection will contribute. for proper management of the disease and its potentially severe complications. live attenuated vaccines and subunit candidate vaccines, which are under clinical evaluation, first induce an antibody response to the virus and minimal cross-reactive t-cell responses. Currently, there are no tools available to access protective T-cell responses during infection or after vaccination. The present invention incorporates immunoproteomics to discover novel hla-a2 specific epitopes derived from dengue virus (dv) infected cells. such epitopes are conserved by cross-reacting epitope-specific ctls against all four dv serotypes. Such epitopes have potential as new information and diagnostic tools to characterize T-cell immunity in dengue virus (dv) infection, and serve as a universal candidate vaccine complementary to current vaccines.